DA-6886

DA‑6886 is a novel small molecule drug developed as a highly potent and selective agonist of the serotonin 5-hydroxytryptamine receptor 4 (5‑HT4). It has been investigated primarily for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and other gastrointestinal motility disorders. DA‑6886 exhibits high affinity and selectivity for human 5‑HT4 receptor splice variants (notably 5‑HT4a, 5‑HT4b, and 5‑HT4d), with minimal activity at other receptors except some affinity for the 5‑HT2B receptor. In preclinical studies, it accelerated colonic transit in animal models of normal and chemically induced constipation. The drug was discovered by Dong-A ST (Dong-A Pharmaceutical Co., Ltd.) in South Korea and has reached phase I clinical trials in humans[3][7][8].

Other names

Benzamide, 4-amino-5-chloro-2-methoxy-N-((1-(3-(1H-1,2,3-triazol-1-yl)propyl)-4-piperidinyl)methyl)-